AXDX:NSD-Accelerate Diagnostics, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 10.40

Change

-0.30 (-2.80)%

Market Cap

USD 0.60B

Volume

0.15M

Average Target Price

USD 17.33 (+66.67%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

+13.31 (+4.88%)

USD39.96B 63.82 38.10
DXCM DexCom, Inc

-4.04 (-1.05%)

USD38.12B 180.97 113.10
IDXX IDEXX Laboratories, Inc

+1.60 (+0.44%)

USD30.95B 66.96 45.42
EXAS Exact Sciences Corporation

+19.96 (+26.85%)

USD11.16B N/A N/A
GH Guardant Health, Inc

+0.55 (+0.52%)

USD10.52B N/A N/A
ICLR ICON Public Limited Company

+1.23 (+0.69%)

USD9.36B 30.15 20.39
QDEL Quidel Corporation

-4.25 (-2.17%)

USD8.23B 56.18 34.83
PRAH PRA Health Sciences, Inc

-1.89 (-1.93%)

USD6.26B 31.73 18.76
SYNH Syneos Health, Inc

-0.62 (-1.18%)

USD5.40B 30.58 17.56
NTRA Natera, Inc

+2.55 (+4.09%)

USD5.24B N/A N/A

ETFs Containing AXDX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.46% 22% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.46% 22% F 21% F
Trailing 12 Months  
Capital Gain -50.76% 19% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.76% 17% F 11% F
Trailing 5 Years  
Capital Gain -39.78% 38% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.78% 35% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain 3.06% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.06% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.99% N/A N/A N/A N/A
Risk Adjusted Return 7.11% N/A N/A N/A N/A
Market Capitalization 0.60B 54% F 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -9.31 69% D+ 81% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -837.84% 5% F 1% F
Return on Invested Capital -48.46% 37% F 20% F
Return on Assets -31.71% 24% F 12% F
Debt to Equity Ratio -1,762.34% 97% A+ 100% A+
Technical Ratios  
Short Ratio 40.49 2% F 0% N/A
Short Percent 46.73% 2% F 4% F
Beta 2.57 6% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector